Castellum, Inc. is a defense-focused technology company headquartered in Vienna, Virginia, serving primarily the U.S. federal government. The company provides cybersecurity, software development, systems engineering, information and electronic warfare, program support, and data analytics services, along with specialized expertise in artificial intelligence and machine learning, 5G technologies, model-based systems engineering, and CMMC compliance.
Castellum has grown largely through disciplined acquisitions, completing seven since 2019, and now operates through subsidiaries including Corvus Consulting, Specialty Systems, and Global Technology and Management Resources. A key competitive differentiator is the company's CMMC Level 2 C3PAO certification, one of a limited number of such certifications, which creates meaningful barriers to entry in federal cybersecurity contracting. Investors follow the stock for its exposure to durable national security priorities, its debt-free balance sheet, and its expanding base of recurring federal work. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, CTM shares fell approximately 22.7%, declining from a closing price of $0.6275 on September 30, 2026, to $0.485 on October 30, 2026. The move was not a single-day event but rather a steady grind lower that accelerated in the final week of October, when the stock dropped from roughly $0.59 on October 21 to $0.485 by October 30.
The three-month trend has been even more pronounced. From a closing price of $0.7177 at the end of July 2026, the stock has fallen roughly 32% as of late October. After a brief spike above $0.79 in early August, shares sold off sharply following the company's second-quarter earnings report and have trended lower through September and October, with only intermittent bounces.
The most recent leg of the decline has been driven less by company-specific negative news than by persistent technical and sentiment pressure. Castellum announced its third-quarter 2026 earnings release and conference call would be scheduled for November 5, and separately disclosed a $32.8 million modification to its PMA-290 Special Missions contract with the Naval Air Systems Command, a positive development that did not halt the slide.
Earlier in October, several members of the executive team, including the CEO and other officers, reported open-market purchases of shares, a signal some investors interpret as insider confidence. Despite these positive data points, the stock continued to drift lower, suggesting that broader selling pressure in low-priced, small-cap equities and a lack of near-term catalysts outweighed the company's operational news flow during the period.
The quarterly decline traces back to the company's second-quarter 2026 earnings release on August 6. Castellum reported revenue of $13.9 million, essentially flat versus $14.0 million in the prior-year quarter, and a net loss of about $1.1 million, or $0.01 per share. Both figures came in below analyst consensus, which had anticipated higher revenue and break-even earnings, and shares sold off sharply the following session.
The broader narrative over the quarter has been one of a company investing ahead of growth. Management has emphasized front-loaded spending on business development, investor relations, and acquisition activity, funded from its own cash flow, which has compressed near-term earnings. While first-half revenue rose 10% year over year to $28.2 million and the company expects a record full year for revenue, investors have focused on the softer margins and modest losses rather than the longer-term growth trajectory, contributing to the sustained downward pressure. From what I see, this focus on near-term results has overshadowed the pipeline strength.
Investors should monitor Castellum's third-quarter 2026 earnings release scheduled for November 5, which will provide an updated view on revenue growth, margins, and the progress of its large Navy prime contracts. Commentary on backlog conversion, the ramp of the PMA-290 and NAWCAD Lakehurst programs, and any new contract awards will be closely watched, as these are the primary drivers of the company's multi-year revenue outlook.
Beyond earnings, key factors include the pace of organic growth versus acquisition investment, gross margin trends as direct labor mix improves, and the status of the company's $953.5 million qualified pipeline. Broader market conditions, particularly sentiment toward small-cap and micro-cap equities, will also remain relevant given the stock's recent volatility. As with any investment, these factors carry inherent uncertainty, and past performance does not guarantee future results. I'm watching this closely as the earnings date approaches.
In my own analysis process, I often turn to Tickeron’s AI Trading Bots to review automated strategies that can complement manual research on names like this. The platform offers a range of bots with different holding periods and performance metrics, which helps put current price action into a broader, data-driven context without replacing individual due diligence.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CTM saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 12, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In 39 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CTM as a result. In 77 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for CTM entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where CTM advanced for three days, in 191 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
CTM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.281) is normal, around the industry mean (2.620). P/E Ratio (-16.167) is within average values for comparable stocks, (17.865). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.284). Dividend Yield (0.000) settles around the average of (0.172) among similar stocks. P/S Ratio (1.076) is also within normal values, averaging (139.965).
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. CTM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CTM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry InformationTechnologyServices